Through network pharmacology and molecular docking, our study found that the main ferroptosis-related targets involved in GA treatment of IDD are P53, NRF2, and PPARg, which is consistent with previous research results (Dodson et al., 2019; Xie et al., 2016; Han et al., 2021). The gene discussed is NFE2L2; the disease is intervertebral disk degenerative disorder.